KRAS and pancreatic adenocarcinoma: In sum, loss of EFR3A (and/or EFR3B) expression inhibits oncogenic signaling in human KRAS-mutant pancreatic adenocarcinoma cells, which manifests as a reduction in transformed and tumorigenic growth.